Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult · Cervical Cancer · Colorectal Cancer · Esophageal Cancer · Esophageal Squamous Cell Carcinoma · Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Head and Neck Squamous Cell Carcinoma · Melanoma · Merkel Cell Carcinoma · Microsatellite Instability-High Solid Malignant Tumor · Mismatch Repair Deficient Solid Malignant Tumor · Microsatellite Instability-High Colorectal Cancer · Mismatch Repair Deficient Colorectal Cancer · Non-small Cell Lung Cancer · Renal Cell Carcinoma · Small Cell Lung Cancer · Squamous Cell Carcinoma · Urothelial Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 134 (planned)
- Started
- Nov 1, 2023
- Main results expected
- Feb 28, 2027
- Fully finished
- Aug 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain
Measured over: 6 months
Phase 1: Identify the maximum tolerated dose (MTD) of NEO212
Measured over: 6 months
Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212
Measured over: 6 months
Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain
Measured over: 6 months
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.
Measured over: 6 months
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.
Measured over: 6 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06047379 · record last updated 2026-09-24 · checked 2026-11-09 15:47 UTC